AntiCancer to test its methioninase as a new treatment for coronavirus
Category: #health  By Mateen Dalal  Date: 2020-02-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

AntiCancer to test its methioninase as a new treatment for coronavirus

The threat of coronavirus needs to be addressed as early as possible, particularly since there are no particular treatments or vaccines currently available for patients suffering from coronavirus globally. As the count of patients infected by the 2019-nCoV reaches 10,000 and death toll hits the 200 mark, with both these numbers rapidly growing, without any particular vaccination for at least one year, the situation is turning dire.

AntiCancer Inc, a US-based biopharmaceutical company, reportedly announced its plans to test its methionine as a treatment for the Coronavirus, the current outbreak of the disease is widely spreading across China and steadily making its way around the world.

AntiCancer’s oral recombinant methioninase specifically targets circulating methionine in the patient’s body. Methionine is a type of amino acid that is derived from food that is rich in protein. Oral methioninase has proven to be highly capable of treating cancer, diabetes, and obesity by limiting methionine in the body.

It is proved that virally infected cells are destroyed by methionine restriction. More importantly, coronaviruses have a particular requirement for methionine to replicate and be able to evade the host’s immune system.

Methioninase project leader at AntiCancer, Dr. Qinghong Han stated that oral recombinant methioninase has the capability to reduce or arrest infection of coronavirus (2019-nCoV) in patients, without and with symptoms.

Han further added that the company would first test methioninase with cultured lung cells that are infected by the 2019-nCoV in vitro. After this, the second test would assess the oral recombinant methioninase in patients infected by the virus.

AntiCancer would conduct all these trials in China together with appropriate organizations as well as safety profiles. Oral recombinant methioninase would be an effective treatment for 2019-nCoV disease as coronaviruses also have a special demand for methionine, Han added.

AntiCancer would partner with AntiCancer Beijing, its sister company located in Beijing, in order to develop oral recombinant methioninase for coronavirus (2019-nCoV) in China. AntiCancer is a San Diego based company and its subsidiaries are in Seoul, Tokyo, Nanjing, and Beijing.

 

Source credit: https://www.streetinsider.com/Business+Wire/AntiCancer+Inc.+to+Target+Its+Oral+Recombinant+Methioninase+Against+2019-nCoV+Coronavirus/16402763.htm

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...